ICTM logo
Join our STAMPEDE Twitter Q&A – Research and Treatment to #BeatProstateCancer

01 November 2018

On Thursday 15 November, we’ll be running a Twitter Q&A session about the STAMPEDE trial – with the hashtag #BeatProstateCancer.

The Twitter Q&A is to raise awareness of prostate cancer research, and highlight how the STAMPEDE trial aims to improve the way in which prostate cancer is currently managed, and enable men to live longer and enjoy a better quality of life.

Prostate cancer accounts for around one fifth of all male cancers. In the UK there are around 47,000 new cases each year and around 10,800 deaths. Most men with prostate cancer are given hormone therapy and this is often effective for a short time at stopping the tumour growing. However, in most cases over time the tumour will start to grow again.

The aim of this trial is to try to prevent the tumour re-growth by adding other treatment to the hormone therapy. The trial is currently assessing abiraterone and enzalutamide in combination with hormone therapy or radiotherapy (newly diagnosed metastatic patients only) in combination with hormone therapy.

We’ve got a panel of experts ready and waiting to answer your questions, and to hear your experiences, or thoughts, on prostate cancer research and treatment.

Our panel

 Matthew Hobbs  

Matthew Hobbs, Deputy Director of Research, Prostate Cancer UK (PCUK)

Matthew is the Deputy Director of Research at PCUK. His role involves making sure PCUK fund the research that has the best chance of making a difference to men affected by prostate cancer, and growing the amount they have to spend on research, and the speed that research makes a difference for men.

 David Matheson  

David Matheson, Patient Representative, STAMPEDE Trial

Spouse of one, father of three, grandfather of four, David is an educationist, teacher and researcher. He is a volunteer speaker for PCUK, and is one of the patient representatives for the STAMPEDE Trial.

 Chris Parker  

Chris Parker, Clinical Oncologist, Royal Marsden Hospital, Sutton

Chris Parker is an oncologist specialising in prostate cancer at the Royal Marsden hospital. He has led prostate cancer trials testing the use of active surveillance for localized disease, post-operative radiotherapy for locally advanced disease and of radium-223 for bone metastases. He is keen to see patient care informed by good quality evidence from clinical trials.

 Matthew Sydes  

Matt Sydes, Reader in Clinical Trials, MRC CTU at UCL

Matt Sydes is a statistician and trialist at MRC Clinical Trials Unit at UCL. He has been involved in the design, conduct and analysis from the start of discussions. He is very keen to share the practical lessons from the trials so that other people might be encouraged to do similar. He continues to be amazed at just how the UK clinical community has engaged in the trial.

How to get involved!

Our panellists will be ready to answer questions from 2.15 pm until 3.00pm on Thursday 15 November (GMT).

You can tweet within this 45-minute slot, or tweet your question before the session begins if you prefer.  If you would like to participate but are not on Twitter, you can also email us your questions in advance.

To ask a question, just tweet using the hashtag #BeatProstateCancer. One of our panel will then reply to you from the @MRCCTU account.

As we have more than one panel member for our Q&A, the person who is answering your question will put their initials at the start of their tweet, so you know who is talking.

As well as answering your questions, we're also very interested to hear what you think - so if you want to contribute, tweet using the #BeatProstateCancer hashtag.

We will post a summary of the Q&A session on our website after the event, so even if you are not a Twitter user you can still see what was said.

Further information

@MRCCTU Twitter page

Read more about the STAMPEDE results

Read more about the STAMPEDE study

STAMPEDE website